Why Does Valnemulin Premix Homogeneity Fail Below 2 kg/Tonne in Swine Feed?

Brachyspira hyodysenteriae challenge models and field outbreaks in grower-finisher pigs create a narrow medicated-feed processing window because infected animals reduce solid feed intake by 30–50% within 48 hours of clinical diarrhoea while water intake often continues. Homogeneity and dose accuracy of valnemulin HCl in complete feed therefore become the controlling parameters, not only total active material added. In a 10% valnemulin premix, final feed inclusion rates of 75–200 mg active/kg complete feed are calculated from target doses of 3.75–5.0 mg/kg body weight/day for 7–14 days; 200 mg/kg is applied for acute swine dysentery and 75 mg/kg for prevention or post-exposure metaphylaxis where the relevant national summary of product characteristics authorizes the lower rate. A 10% premix is added at 2.0 kg per tonne to produce 200 mg active/kg final feed, while a 5% premix requires 4.0 kg per tonne. Production of the intermediate premix on 500–1000 kg double-ribbon mixers requires a two-stage geometric dilution. The active substance is first screened through a 500 µm conical mill with an equal mass of lactose monohydrate and 1.0% w/w colloidal silicon dioxide, then extended with maize starch or rice hull carrier to 5% or 10% potency. Fill ratio is maintained at 60–70% of nominal mixer volume; validated mixing at 14–16 rpm for 15 minutes achieves blend uniformity coefficient of variation ≤5.0% by HPLC assay of 10 stratified samples drawn according to ISO 6497:2005 and prepared according to ISO 6498:2012. Addition of 0.5–1.0% w/w mineral oil after the active blending step reduces dust and electrostatic segregation, but oil must be added only after the API has been dispersed, never to an unmixed API layer. A final post-blend analytical check for assay and moisture is performed before packaging into 25 kg multi-wall paper bags with LDPE liners. Carrier pH above 9.5—typical of some limestone diluents—is incompatible because pleuromutilin lactone hydrolysis accelerates under alkaline conditions. Storage at ≤25 °C and ≤40% relative humidity is specified, and the premix is kept sealed because the hydrochloride salt is hygroscopic. Manufacturer line-clearance protocols are critical after ionophore coccidiostats because pleuromutilins and polyether ionophores have documented interaction potential in swine and poultry. Where feed-safety systems are aligned with US-bound feed intermediates, hazard analysis and preventive controls follow 21 CFR Part 507. The terminal product type is a 5% or 10% valnemulin HCl medicated premix in 25 kg lined bags for feed-mill addition.

Porcine proliferative enteropathy granulation for water application uses a high-shear route because the API's hygroscopicity creates auger bridging in direct dry blending when the particle size distribution falls below 50 µm. Water-soluble valnemulin HCl granules are produced at 50% activity with lactose monohydrate as the main soluble filler and povidone K30 as binder; 100 g of 50% granules dissolved in 1000 L drinking water gives 50 mg active/L, and the final medicated water concentration is adjusted to the veterinarian's directed dose of 3.75 mg/kg body weight/day using current water intake measurements. The production process is granulation in a 250 L high-shear mixer at impeller speed 250 rpm and chopper speed 1200 rpm with 12–14% w/w binder solution, discharge of the wet mass through a 1.5 mm screen, drying in a fluid-bed dryer at inlet air 55–60 °C to loss on drying ≤2.0%, and sizing of dried granules to 150–500 µm using an oscillating granulator. Dissolution of the finished granule is checked under Ph. Eur. 2.9.3 using 900 mL water at 15 °C and paddle speed 50 rpm; a release criterion of ≥80% dissolved in 5 minutes is applied where national specifications require. Dose unit uniformity for sachets is evaluated under Ph. Eur. 2.9.40. The granule formulation must not be dry-mixed with citric acid or other crystalline acids because localized pH below 3.0 accelerates acid hydrolysis of the pleuromutilin side chain; if drinking water is chlorinated above 2 mg/L free chlorine, 0.01% w/v sodium thiosulfate is added by the end user before reconstitution. Residual-solvent control follows VICH GL18, and impurity profiling follows VICH GL11. Primary packaging is PET/aluminium/LDPE sachet strip of 100 g and 1 kg; the product is labelled for 24-month shelf life at ≤25 °C with sachet integrity testing according to ASTM F2096-11. The terminal product type is a 50% water-soluble valnemulin HCl granule in single-dose or multi-dose sachets for on-farm reconstitution.

When Chlorinated Drinking Water Destabilises Water-Soluble Valnemulin Powders in Poultry Systems

In authorized poultry indications, Mycoplasma gallisepticum and Mycoplasma synoviae outbreaks require flock-level medication through nipple or bell drinkers, where water line biofilms, galvanized metal pipes, and fluctuating pH alter soluble drug delivery. Valnemulin HCl 10% water-soluble powder is formulated for 100 mg active/L final drinking water by adding 1.0 kg of powder to 1000 L water, with a working range of 50–100 mg/L depending on susceptibility results and national labelling; treatment courses run 3–5 days in most authorizations. The powder is manufactured by spray-dried lactose carrier blending rather than high-shear granulation because poultry water systems deliver the dose by rapid reconstitution, not by sustained granule dissolution. Production involves blending the micronized API with spray-dried lactose at 100–200 µm particle size, 1.0% w/w anhydrous citric acid–sodium citrate buffer to control reconstituted pH at 4.0–5.5, and 0.1% w/w silica as antistatic, followed by 10-minute tumble blending at 75% fill in 500 L V-blenders. Moisture content is limited to ≤1.5% by Karl Fischer titration. Reconstituted solution stability in water lines is pH-dependent; pH above 7.5 and standing water at ambient temperature above 25 °C for more than 12 hours are considered operational limits because pleuromutilin esters undergo alkaline hydrolysis. Metallurgical compatibility is also relevant: galvanized pipes with zinc corrosion products raise local pH and may reduce potency; high-density polyethylene and 316L stainless steel lines are preferred. Microbial limits comply with Ph. Eur. 5.1.4 for non-sterile oral preparations, and antimicrobial susceptibility is interpreted under CLSI VET01 when monitoring flock resistance. Polyether ionophore coccidiostats such as monensin, salinomycin, or narasin should not be present in feed during treatment due to documented toxic interaction risk in poultry. The terminal product type is a 10% valnemulin HCl water-soluble powder in 1 kg and 5 kg PET/aluminium/LDPE pouches.

Injectable-grade valnemulin HCl represents a formulation niche for severe porcine dysentery and acute enteropathy in which feed and water intake are depressed for 24–48 hours and systemic administration is requested under veterinary discretion. Published data for this specific configuration is limited; manufacturer development reports describe 5.0% w/v and 7.5% w/v candidate solutions prepared in an aqueous vehicle adjusted to pH 4.5–5.5 with acetate buffer and made isotonic with 0.9% w/v sodium chloride or 5% w/v dextrose. A 5.0% w/v solution delivers 50 mg active/mL; a 1.0 mL dose per 10 kg body weight yields 5.0 mg/kg intramuscularly. The production route for investigational batches is aseptic compounding: dissolution in pyrogen-free water, pH adjustment, 0.22 µm PVDF membrane filtration, and filling into 100 mL amber borosilicate glass vials under Grade B/ISO 5 conditions. Terminal steam sterilisation at 121 °C for 15 minutes is contraindicated because hydrolytic degradation increases rapidly above 70 °C in aqueous media, so sterile filtration is the only practical sterilisation route. Sterility is verified under USP <71>, subvisible particulate matter under Ph. Eur. 2.9.19 or USP <788>, and endotoxin control under Ph. Eur. 2.6.14. The solution must not be frozen, and repeated intramuscular injection at the same site is avoided due to local irritation documented for acidic pleuromutilin formulations. No harmonized pharmacopoeial monograph exists for valnemulin injection, so release specifications are set against the API monograph, VICH GL11 impurity limits, and VICH GL18 residual solvent limits. The clinical use is restricted to jurisdictions where the injectable route is authorized or where veterinary prescription allows extralabel use consistent with local residue and withdrawal rules. The terminal product type is a 100 mL sterile injectable solution in a type II amber glass vial with butyl rubber stopper and aluminium flip-off seal.

Low-Humidity Granulation Limits for Valnemulin HCl Tablet and Capsule Cores

Solid oral dosage forms of valnemulin HCl are manufactured for national markets where tablet or capsule registration exists and for non-food animal use under veterinary supervision; they are not globally harmonized presentations. Tablet cores at 25 mg and 50 mg activity use the API at 5–15% w/w of the core formula depending on dose unit, with microcrystalline cellulose 40–60% w/w, lactose monohydrate 20–35% w/w, croscarmellose sodium 2–3% w/w, and povidone K30 3–5% w/w as binder. The process is a low-shear wet granulation: dry blend for 10 minutes in a 250 L planetary mixer, add purified water or isopropyl alcohol–water binder, pass the wet mass through a 0.8 mm screen, dry in a fluid-bed dryer at inlet air 50–55 °C to loss on drying ≤2.0%, and mill to 200–500 µm. Tablets are compressed on a rotary tablet press at 8–12 kN for a 10 mm flat bevel punch; hardness is monitored alongside friability ≤1.0% under Ph. Eur. 2.9.7 and disintegration ≤15 minutes under Ph. Eur. 2.9.1. Capsules are filled with the same granules into size 3 or size 4 hard gelatin or HPMC shells to provide 25 mg or 50 mg activity. Uniformity of dosage units is tested under Ph. Eur. 2.9.40. Because valnemulin HCl is hygroscopic, the tabletting suite is maintained at ≤30% relative humidity and 20–22 °C; aqueous binder granulation is preferred, but drying must not exceed 55 °C to avoid degradation. Residual-solvent and impurity profiles conform to VICH GL18 and VICH GL11. Dissolution testing is conducted under Ph. Eur. 2.9.3 using 900 mL water at 37 °C, with specifications set by national registration files. The terminal product type is a 10-tablet or 10-capsule aluminium/PVC blister for solid oral dosing.

Feed top-dress microgranules for individual piglet treatment are prepared as a low-dust alternative to water medication when in-line dosing is unreliable or water intake is variable. The formulation addition ratio is derived from the target of 3.75 mg active/kg body weight/day; a 20 kg piglet receiving 100 g of top-dress feed carries 75 mg active if the full daily dose is consumed, corresponding to 750 mg active/kg top-dress. Production uses a bottom-spray Wurster fluid-bed coater: inert lactose-starch starter spheres are coated with a valnemulin HCl dispersion containing 5% povidone K30 binder at inlet air 45–50 °C, followed by 0.2% w/w silicon dioxide as anti-caking agent. The coated granules are sized to 300–800 µm to minimise segregation in low-volume feed top-dress applications. Uniformity of mass for single-dose sachets is checked under Ph. Eur. 2.9.5, and content uniformity under Ph. Eur. 2.9.40 where the product is packed as measured-dose pouches. The microgranules are packaged in 1 kg HDPE jars with foil induction seals; product moisture is maintained at ≤2.0%, and the jar headspace is flushed with nitrogen if extended storage beyond 12 months is specified. The formulation is incompatible with simultaneous oral dosing of polyether ionophores, and water used for reconstituting or flushing must not exceed 2 mg/L free chlorine. Local withdrawal periods and residue control programs are set by national authorization because tissue residue kinetics differ between feed, water, and top-dress routes.